Farallon Capital Management LLC Makes New $13.91 Million Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Farallon Capital Management LLC acquired a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,000,981 shares of the company's stock, valued at approximately $13,914,000. Farallon Capital Management LLC owned approximately 1.98% of Tyra Biosciences at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. RA Capital Management L.P. increased its position in Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after buying an additional 220,681 shares in the last quarter. Alta Partners Management Company L.P. bought a new stake in Tyra Biosciences in the 4th quarter valued at about $56,716,000. Boxer Capital Management LLC bought a new stake in Tyra Biosciences in the 4th quarter valued at about $28,185,000. JPMorgan Chase & Co. increased its position in Tyra Biosciences by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after buying an additional 3,896 shares in the last quarter. Finally, Pictet Asset Management Holding SA bought a new stake in Tyra Biosciences in the 4th quarter valued at about $4,921,000. 84.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on TYRA shares. HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Monday, March 31st. Wedbush reiterated an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a research note on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Tyra Biosciences presently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Trading Up 0.2%

Shares of NASDAQ:TYRA traded up $0.02 on Friday, reaching $10.09. 394,066 shares of the company traded hands, compared to its average volume of 260,055. The business's 50-day simple moving average is $9.64 and its 200 day simple moving average is $13.10. Tyra Biosciences, Inc. has a 52 week low of $6.42 and a 52 week high of $29.60. The stock has a market capitalization of $535.68 million, a P/E ratio of -6.27 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Sell-side analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.